Table 3. Mean values of host makers detected in saliva samples of TB patients at baseline, month 2 and month 6 (after the start of TB treatment).

	Time point			P value
Marker	Baseline	Month 2	Month 6	Baseline Vs. M2	M2 Vs. M6	Baseline Vs. M6
CRP	16 (12.7–19.5)	13.2 (9.8–16.6)	14.2 (9.9–18.5)	0.015	0.27	0.21
ECM-1	22 (15.9–28.2)	15.5 (8.4–22.6)	12.6 (4.4–20.7)	0.12	0.63	0.063
ENA -78	35 (8.6–61.6)	107.7(42.2–173.1)	125 (39–211.4)	0.015	0.88	0.020
Haptoglobin	1664.6(905.1–2424.1)	845(295.2–1398.7)	935.2(181.91–688.4)	0.029	0.81	0.076
IL-17A	13.4 (9–17.9)	8.2 (4.7–11.7)	9 (3.6–14.3)	0.064	0.74	0.16
IL-23	0.81 (0.36–1.25)	0.38(0.036–0.72)	0.35 (-0.1–0.81)	0.083	0.83	0.17
IP-10	70 (24.3–115.4)	113.4(67.7–159.1)	137.6 (59.3–216)	0.11	0.49	0.040
Lipocalin-2	1415.5 (750.2–2080.8)	1393.2 (749.3–2037.1)	1097.6(425.58–1769.646)	0.62	0.053	0.027
MIP-1 β	16.2 (10.1–22.3)	17.6 (10–25.3)	23.7 (11.3–36)	0.38	0.098	0.022
SDF-1a	421.2 (324.4–518)	275.4 (151.7–399)	333.5 (164–503.1)	0.080	0.51	0.33
Transthyretin	1810.9(1577.4–2044.5)	1817.6(1611.4–2023.9)	1922.2 (1686.4–2158)	0.75	0.047	0.12
VEGF	355.5 (261.4–450)	392.2(304–480.4)	447 (359–535)	0.18	0.30	0.034

Data were analysed using mixed model repeated measures analysis of variance, with Fisher’s Least Significant Difference post hoc testing. The mean values shown (95% confidence intervals in brackets) are the least squared means. Significant P-values are in bold